Join Dr. Faranak Kamangar, MD, every week as she chats with various guests about the future of dermatology. Each week, Dr. Kamangar and her guests cover topics from psoriasis, to eczema, to skin care, to AI, and more. Whether you’re a doctor or a patient, these episodes provide valuable information about your skin and how to navigate the world of dermatology.
The Future of Dermatology
Claim This Podcastby thefutureofdermatology
4.7(12 reviews)
135 episodes
Updated Daily
Accepts GuestsHas SponsorsLocation 🇺🇸
49
Podcast Authority
BetaFairBased on show quality, social media presence, reviews, charts, and more
Quality55
Social0
YouTube76
Engagement32
Podcast Overview
Join Dr. Faranak Kamangar, MD, every week as she chats with various guests about the future of dermatology. Each week, Dr. Kamangar and her guests cover topics from psoriasis, to eczema, to skin care, to AI, and more. Whether you’re a doctor or a patient, these episodes provide valuable information about your skin and how to navigate the world of dermatology.
Language
🇺🇲
Publishing Since
9/19/2023
Unlock The Full Podcast Authority Score Report
See how your podcast performs across key metrics
49
Podcast Authority
BetaFairBased on show quality, social media presence, reviews, charts, and more
Quality55
Social0
YouTube76
Engagement32
8
Excellent Areas
0
Good Performance
11
Growth Opportunities
excellent
Publishing Consistency
Every 7 days
Performing excellently!
poor
Episode Thumbnails
Recommendations available
Unlock the full report to see detailed tips
+16 More Metrics
Unlock comprehensive insights including:
- • YouTube presence analysis
- • Social media reach metrics
- • RSS compliance scoring
- • Podcast 2.0 features
- • Technical standards
What's Included in Your Full Report
Detailed Analytics
- Complete breakdown of all 19 authority metrics
- Personalized recommendations for each metric
- Industry benchmarks and comparisons
- Technical RSS feed analysis and compliance scoring
Growth Strategies
- Step-by-step action plans for improvement
- Quick wins to boost your score immediately
- Pro tips from successful podcasters
Get your free podcast insights report
See how your show performs across every key metric
Instant delivery
No spam
Attract Better Guests
High authority scores make your podcast more attractive to industry leaders and influencers who want to appear on credible shows.
Secure Sponsorships
Sponsors look for podcasts with proven authority and engagement. Your score demonstrates your podcast's value to potential partners.
Grow Your Audience
Understanding your strengths and weaknesses helps you make data-driven decisions to expand your listener base effectively.
Reach the team behind The Future of Dermatology
Verified contact details for this show aren't on file yet — sign up to get notified when they land.
Recent Episodes
June 2, 2026
Episode 133: HS Treatment Pipeline Explosion: What's New & What's Next | The Future of Dermatology Podcast
Summary: Hidradenitis Suppurativa (HS) is one of dermatology's most complex and underrecognized conditions and the treatment landscape is changing fast. In this episode, Dr. Faranak Kamangar sits down with Dr. Hadar Lev-tov, Associate Professor at the University of Miami, Director of the Wound Healing Fellowship, and Immediate Past President of the Hidradenitis Suppurativa Foundation, for a rapid-fire review of everything happening in the HS world right now. Dr. Lev-tov covers the currently approved therapies, the exciting drugs moving through Phase 3 trials, and the groundbreaking science linking microplastics to HS inflammation. He also shares his candid take on GLP-1s in HS management and what the future of dermatology looks like when treatments work so well that doctors can finally focus on the whole patient. Whether you're a resident just learning HS or a seasoned dermatologist trying to keep up with a fire-hose pipeline, this one is for you. Topics Covered: - Approved HS biologics: bimekizumab, secukinumab, adalimumab & biosimilars- Off-label use of infliximab (IV and subcutaneous) in severe HS- Phase 3 pipeline: remibrutinib, povorcitinib, sonelokimab (nanobodies)- CAR T-cell therapy and the possibility of curing inflammatory skin disease- Microplastics, nicastrin, and a landmark Nature Communications paper on HS- GLP-1s in HS: what we know, what we don't, and Dr. Levtov's clinical approach- The HS Foundation's research grants, HS Academy, wound care referral tool, and prior authorization templates- The future of dermatology as lifestyle medicine Resources Mentioned: - https://www.nature.com/articles/s41467-025-65789-7 - HS Foundation website & prior authorization templates: https://www.hs-foundation.org/- HS Academy (free weekend for residents): https://www.hs-foundation.org/hs-academy- Integrative Dermatology Symposium: integrativedermatologysymposium.com- LearnSkin: learnskin.com This podcast is for educational purposes only and is not a substitute for professional medical advice. Always consult your healthcare provider. Key Takeaways: 1. Validate HS patients the moment they walk in. They've often been dismissed or bounced between providers for years. Simply saying "I understand what you're going through" builds trust immediately and makes the visit more productive. 2. The approved HS treatment arsenal is growing. Bimekizumab and secukinumab (IL-17 inhibitors) are now approved, and adalimumab — including biosimilars — remains a valuable option. Clinical experts are using biosimilars with confidence. 3. Subcutaneous infliximab is an emerging option. Available off-label in the US, new data from French centers shows a protocol: standard IV induction at weeks 0, 2, and 6, then switching to subcutaneous injections every two weeks at week 10 — but only once the patient is in strong remission. 4. Three major drugs are in or completing Phase 3 trials. Remibrutinib (BTK inhibitor, already approved for chronic spontaneous urticaria), povorcitinib (JAK1 inhibitor), and sonelokimab (a nanobody targeting IL-17A and IL-17F) are all reporting promising results and moving toward FDA application. 5. Nanobodies are a technology to watch. Derived from camelid antibody fragments, nanobodies like sonelokimab can be engineered to target multiple pathways simultaneously in a smaller, more modular molecule — expect to see them across dermatology. 6. Half-life extenders could mean one injection per year. Already emerging in psoriasis, these extended-dosing biologics are heading toward HS — a potential game-changer for patient adherence. 7. CAR T-cell therapy may one day cure inflammatory skin disease. Currently being studied in lupus and rheumatoid arthritis, the protocols are becoming more practical, and the technology is edging toward dermatology. 8. Microplastics may potentiate HS inflammation. A Nature Communications paper by Dr. Luis Garza (Hopkins) found that plastic-associated endocrine disruptors block nicastrin i
May 19, 2026
Episode 132: Behind the Scenes: Podcast Milestones, SF Derm 2026, & Derm GPT | The Future of Dermatology Podcast
📋 Summary:In this special behind-the-scenes episode, Dr. Faranak Kamangar welcomes podcast producer Steph Cullen on camera for the first time in two years. Together they reflect on over three years of building the Future of Dermatology podcast, now a top dermatology-facing podcast with 130+ episodes, 40,000+ total plays across all platforms, and over 700 downloads a month, all achieved with zero paid marketing. Dr. Kamangar shares exciting updates happening this summer, including the opening of her new Palo Alto practice in August, the upcoming SF Derm 2026 conference (August 28–30 at the Four Seasons Silicon Valley in Palo Alto), and the explosive growth of DermGPT, her AI tool built specifically for dermatologists and derm providers. She also celebrates her recognition on the Inc. Female Founders 500 list for her work in health tech AI. The conversation covers what makes this podcast stand out - a steadfast commitment to evidence-based, science-forward dermatology content - and looks ahead to the future, including expanding the guest roster geographically, a possible move into short-form content, and a growing focus on AI in dermatology. Whether you're a longtime listener or just discovering the show, this episode is a candid, energetic look at what's been built and what's coming next. Register for SF Derm 2026! https://www.sfderm.org/ ✅ Key Takeaways: 1. The podcast has grown organically to become a top dermatology-facing show. With 130+ episodes, 40,000+ total plays, and over 700 monthly downloads across Spotify, Apple, and YouTube - all without paid promotion or leaderboard platforms - the Future of Dermatology has become one of the most listened-to dermatology podcasts available. 2. Staying science-first has been the secret to longevity. Dr. Kamangar and Steph emphasize that resisting the temptation to chase trending or sensational topics in favor of solid, evidence-based science is what built a loyal, engaged audience of dermatologists, providers, and interested listeners. 3. SF Derm 2026 is shaping up to be the biggest one yet. The conference runs August 28–30 at the Four Seasons Silicon Valley in Palo Alto. Highlights include a tech-forward AI and derm panel featuring physicians from Stanford and Harvard, a metabolic and HS/vulvar disease panel, a hormones talk by an OB-GYN, grand rounds, resident jeopardy, and a Saturday night "1001 Nights" themed party. 4. DermGPT has reached over 23,000 dermatology providers - with more than 5,000 using it regularly - built by a team of just three people with no marketing budget. Dr. Kamangar built this tool out of a recognized need: dermatology makes up less than 2% of the house of medicine, making it an overlooked target for health tech development, yet burnout from administrative burden is high. 5. AI is about giving doctors time back, not replacing them. The episode makes a compelling case that AI tools like DermGPT are most valuable not for replacing clinical judgment, but for reducing "pajama time" - the hours physicians spend on documentation and inbox management after hours - so they can focus on the work they're most passionate about. 6. The podcast has begun influencing larger media. A patient episode on atopic dermatitis caught the attention of Time Health, who reached out to feature the guest. This kind of organic mainstream crossover validates the show's mission to bring credible dermatology science to wider audiences. 7. There are dermatology deserts across the U.S. The episode briefly touches on geographic disparities in dermatology access, with Steph noting the growing need for telehealth solutions. Dr. Kamangar acknowledges the podcast's current West Coast bias and invites listeners to recommend guests from underrepresented regions. 🕐 Chapters:00:00:01 — Welcome & Introduction00:00:54 — Meet Steph Cullen: The Face Behind the Scenes00:02:33 — Three Years, 130+ Episodes & 40,000 Plays00:04:53 — Why Staying Science-Forward Has Paid Off00:07:15 — SF
May 5, 2026
Episode 131: HS Updates, Prior Auth Reform & CA Legislation in Dermatology ft. Dr. Haley Naik | The Future of Dermatology Podcast
Summary: In this episode of the Future of Dermatology podcast, host Dr. Faranak Kamangar sits down with Dr. Haley Naik, board-certified dermatologist, professor at UCSF, and Stanford and Harvard-trained expert, for a timely and eye-opening conversation on two major fronts: the rapidly evolving treatment landscape for Hidradenitis Suppurativa (HS) and the critical California state legislation that could reshape how dermatologists practice and how patients access care. Dr. Naik opens with exciting updates in the HS space, including the three currently FDA-approved therapies and two promising agents anticipated to cross the finish line by 2027. She also shares a major advocacy win: HS has been designated a highlighted research topic by the NIH across three institutes, opening a one-year funding window starting April 7, 2026 that researchers should act on now. The conversation then dives deep into the broken prior authorization system, with striking data points: 25% of dermatology visits require prior auth, 75% of denial letters have no listed decision maker, and the average dermatology practice spends $40,000 per year staffing for prior authorizations. Against this backdrop, Dr. Naik breaks down three California bills - two to support and one to oppose - that directly affect how dermatologists can care for their patients. Whether you're a dermatologist, researcher, or patient advocate, this episode is packed with actionable information, from NIH grant deadlines to how to contact your state representative before late June voting deadlines. Learn more and take action:AB539 (prior authorization reform): https://legiscan.com/CA/bill/AB539/2025SB895 (California Science and Health Research Bond Act): https://lnkd.in/gTjXXxtUFind your California representative to advocate for these bills: https://findyourrep.legislature.ca.gov/Information about the May 4th Rally for California Science: https://www.fundcascience.org/rally 🔔 Subscribe for more episodes on the latest in dermatology science, innovation, and advocacy. ⚠️ This podcast is for educational purposes only and does not constitute medical advice. Always consult your healthcare provider. Key Takeaways: 1. Three FDA-Approved HS Therapies Now Available Adalimumab, Secukinumab, and Bimzelx (bimekizumab) are currently FDA-approved for Hidradenitis Suppurativa, giving clinicians meaningful treatment options that didn't exist before 2015.2. Two More HS Therapies Expected by 2027 Povorcitinib (a JAK1 inhibitor by Incyte) and an IL-17A/F nanobody by Moonlake Therapeutics are both anticipated to receive approval in the coming years, with over 50 therapies currently in the HS pipeline.3. NIH Has Designated HS a Highlighted Funding Topic - Act Before April 2027 HS has been named a highlighted research topic across three NIH institutes. This designation runs from April 7, 2026 through April 2027. Researchers interested in HS funding must submit applications within this one-year window.4. The Prior Authorization System Is Widely Acknowledged as Broken Even the Blue Shield CEO publicly admitted the prior auth process is broken. The insurance industry issued a voluntary streamlining pledge in summer 2025. Key pain points include: step therapy requirements, peer-to-peer reviews often conducted by non-physicians, no identified decision maker on 75% of denial letters, and reauthorization periods as short as three months.5. AB 539 Would Extend Prior Auth Approvals to One Full Year Currently, prior authorizations for some medications last as little as three months, forcing practices to repeatedly restart the paperwork process and creating dangerous gaps in patient care. AB 539 would require approved prior authorizations to be maintained for one year (or the full treatment course if shorter). This is especially impactful for HS patients who already face a 7–10 year diagnostic delay.6. AB 2000 Would Ban Mid-Year Formulary Changes If a patient is doing well on a medication, insurers could curre
135 total episodes available
Similar Podcasts
Discover related shows you might enjoy
The Mel Robbins Podcast
Mel Robbins
Cutaneous Miscellaneous: The Dermatology Residents Podcast
Dermsquared
Derms and Conditions
Dermsquared
Derms on Drugs
Scholars in Medicine
Dermasphere - The Dermatology Podcast
Luke Johnson
All-In with Chamath, Jason, Sacks & Friedberg
All-In Podcast, LLC
Dateline NBC
NBC News
The Daily
The New York Times
Crime Junkie
Audiochuck
Deep-dive analytics for The Future of Dermatology
Frequently asked questions
Have a different question and can't find the answer you're looking for? Reach out to our support team by sending us an email and we'll get back to you as soon as we can.
- What is The Future of Dermatology?
- How often does this podcast release new episodes?
This podcast updates daily.
- Where can I listen to this podcast?
This podcast is available on 10 platforms including Apple Podcasts, Spotify, and more. You can also use the RSS feed directly.
- Does this podcast accept guests?
No, this podcast does not typically feature guests.
Legal Disclaimer
Pod Engine is not affiliated with, endorsed by, or officially connected with any of the podcasts displayed on this platform. We operate independently as a podcast discovery and analytics service.
All podcast artwork, thumbnails, and content displayed on this page are the property of their respective owners and are protected by applicable copyright laws. This includes, but is not limited to, podcast cover art, episode artwork, show descriptions, episode titles, transcripts, audio snippets, and any other content originating from the podcast creators or their licensors.
We display this content under fair use principles and/or implied license for the purpose of podcast discovery, information, and commentary. We make no claim of ownership over any podcast content, artwork, or related materials shown on this platform. All trademarks, service marks, and trade names are the property of their respective owners.
While we strive to ensure all content usage is properly authorized, if you are a rights holder and believe your content is being used inappropriately or without proper authorization, please contact us immediately at hey@podengine.ai for prompt review and appropriate action, which may include content removal or proper attribution.
By accessing and using this platform, you acknowledge and agree to respect all applicable copyright laws and intellectual property rights of content owners. Any unauthorized reproduction, distribution, or commercial use of the content displayed on this platform is strictly prohibited.